Today's News | Note: News feeds may no longer be available for the articles on this page.

No Increase in Clots With Drug-Eluting Stents 10:06 AM 3/29/2009
U.S. News & World Report - Washington,DC,USA
There have been concerns that stent thrombosis is more common with drug-eluting stents, but there appears to be no difference from bare metal stents in a large new study. ...

Cholesterol drug not linked to cancer 6:30 AM 3/28/2009
Reuters - USA
A large-scale study suggests that the cholesterol-lowering drug Zetia (ezetimibe) does not increase the risk of cancer. This holds true for Vytorin (ezetimibe and simvastatin). ...

Heart-failure drug on clinical hold: Nile Therapeutics 2:21 AM 3/28/2009
Reuters - USA
Nile Therapeutics Inc said that the US FDA placed a clinical hold on the initiation of a mid-stage trial of CD-NP. It's an experimental drug to treat acute heart failure. ...

Blockbuster Drugs Would Be Compared Under US Proposal 3:35 PM 3/27/2009
Wall Street Journal - USA
The US National Institutes of Health will support "comparative effectiveness" research of certain drugs and health interventions. Criteria point to top-selling drugs. ...

Dyax Pares Decline; No More Trials Needed For Drug Approval 2:01 PM 3/27/2009
Wall Street Journal - USA
Dyax Corp reversed its double-digit stock losses when investors realized that no further trials will be necessary to gain approval. ViroPharma Inc's Cinryze is already approved for attacks of hereditary angioedema. ...

US FDA staff: Avastin brain cancer data unclear 12:05 PM 3/27/2009
Reuters - USA
US FDA documents say that it's difficult to tell how well brain cancer patients responded to Genentech Inc's cancer drug Avastin in early studies. ...

Gilead Sciences: High-Performing Pharmaceutical 4:36 AM 3/27/2009
BusinessWeek - USA
Gilead makes it easier for patients to comply with complex and uncomfortable drug regimens. One of the first companies to come up with once-a-day pills for HIV. ...

Dyax says FDA seeks more data on genetic-disease drug 5:09 PM 3/26/2009
Reuters - USA
Dyax Corp said the US FDA denied approval for its experimental treatment ecallantide for the treatment of acute attacks of hereditary angioedema (HAE). The agency wants additional safety data. ...

Bipartisan Grp Of US Sens Unveil Bill On Generic Biologic Drugs 12:49 PM 3/26/2009
Wall Street Journal - USA
Senators introduced legislation that seems to create a pathway for getting cheaper versions of brand-name biologic drugs to the market. Schumer calls the bill a "down payment on health care reform". Looks more like wishful thinking without any beef. ...

Wal-Mart Retail Muscle Helps Expand Prescription-Drug Program 12:46 PM 3/26/2009
Bloomberg - USA
Wal-Mart's partners bypass a third-party provider and get direct pricing on drugs. Some of those savings get passed on to employees by waiving a $5 co-payment on generic drugs. ...

Novo, Astra-BMS diabetes drugs face US grilling 8:54 AM 3/26/2009
Reuters - USA
Two new diabetes drugs face US experts next week. Novo's Victoza (liraglutide) and AstraZeneca and Bristol's Onglyza (saxagliptin) could face safety issues delaying their US approval. ...

Roche controls 96.2 percent of Genentech as bid closes 5:10 AM 3/26/2009
Reuters - USA
Roche Holding AG controls a total of 96.2 percent of Genentech shares after completing its tender offer for the 44 percent stake it did not already own. Genentech will eventually cease trading on the NYSE. ...

Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR ... 4:33 AM 3/26/2009
FOXBusiness - USA
Vertex Pharmaceuticals Inc initiated a Phase 2a clinical trial for VX-809. The investigational Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) corrector targets the defective CFTR protein that causes cystic fibrosis (CF). ...

US psychiatrists to end drug company seminars 3:04 PM 3/25/2009
Reuters - USA
The American Psychiatric Association representing 38,000 doctors will end medical education seminars and meals sponsored by drug companies at its annual meetings. ...

Biodel shares jump on plans to submit NDA for diabetes drug 2:22 PM 3/25/2009
Forbes - NY,USA
Biodel Inc shares jumped on news that it plans to submit a new drug application for its experimental diabetes drug VIAject. ...

<- Day Earlier | Today's News